Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen clinical trial (NCT06680050). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential side effects of durvalumab and ceralasertib?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen clinical trial (NCT06680050). Contact the study team or your healthcare provider for specific answers.

Question 3

How does this treatment compare to my current options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen clinical trial (NCT06680050). Contact the study team or your healthcare provider for specific answers.

Question 4

What will the treatment schedule look like, and how often will I need to visit the clinic?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen clinical trial (NCT06680050). Contact the study team or your healthcare provider for specific answers.

Question 5

What should I expect during the radiotherapy portion of the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen clinical trial (NCT06680050). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any risks I should be aware of before participating?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen clinical trial (NCT06680050). Contact the study team or your healthcare provider for specific answers.

What this study is about